Key Takeaways
- • Prenetics closed $1 billion in growth financing from General Catalyst's Customer Value Fund, structured as a non-dilutive marketing financing facility covering up to 70% of IM8's customer acquisition spend with capped returns to the investor.
- • IM8 revenue guidance for full-year 2026 raised to $210–$220 million (second upward revision in 2026), with annualized run-rate revenue expected to reach $300 million by year-end 2026 and full-year 2027 revenue projected at $400 million or more.
- • IM8 demonstrates strong unit economics, with every $1 invested in customer acquisition returning $1.44 in gross profit across mature cohorts, and operationally delivering approximately 200,000 servings daily with one order placed every 27 seconds.
- • The financing arrangement preserves equity ownership for Prenetics and IM8 shareholders; General Catalyst receives only a capped share of income tied to cohort performance, with all incremental value reverting to IM8 after the investor recovers its investment and predetermined returns.
- • Prenetics enters the partnership from a position of financial strength, with approximately $139 million in available capital, and July 2026 marked the first month of positive consolidated adjusted free cash flow.
Summary
Prenetics Global Limited announced on July 14, 2026, the closing of a $1 billion growth financing facility from General Catalyst's Customer Value Fund, a non-dilutive arrangement designed to accelerate customer acquisition for IM8, the AI-native direct-to-consumer wellness brand co-founded by David Beckham. The structure reflects an increasingly common model in high-growth consumer health: rather than raising equity or issuing convertible instruments, General Catalyst will finance up to 70% of IM8's marketing spend while receiving a capped share of income tied to monthly customer cohort performance. Once General Catalyst recovers its investment plus predetermined returns on any given cohort, all subsequent value from those customers accrues permanently to IM8.
The financing validates strong underlying unit economics and growth momentum. IM8 has achieved status as the fastest-growing premium supplement brand on record, with over 50 million servings delivered to date and approximately 200,000 servings currently delivered daily. Customer acquisition efficiency stands at $1.44 in gross profit returned for every $1 invested across mature cohorts, indicating sustainable path to profitability at scale. IM8's operational velocity—one order every 27 seconds—demonstrates consistent demand generation and fulfillment capability.
Prenetics simultaneously raised full-year 2026 revenue guidance for IM8 to $210–$220 million, up from the prior $190–$210 million guidance, marking the second upward revision in 2026. The company projects annualized run-rate revenue of $300 million by year-end 2026 and full-year 2027 revenue exceeding $400 million. The company entered the financing from a position of financial strength with approximately $139 million in available capital, and reported that July 2026 was the first month of positive consolidated adjusted free cash flow, expected to persist going forward. This capital-efficient growth strategy—pairing strong inherent unit economics with non-dilutive marketing financing—positions IM8 to accelerate customer acquisition while maintaining balance sheet strength and preserving shareholder equity.
The financing validates strong underlying unit economics and growth momentum. IM8 has achieved status as the fastest-growing premium supplement brand on record, with over 50 million servings delivered to date and approximately 200,000 servings currently delivered daily. Customer acquisition efficiency stands at $1.44 in gross profit returned for every $1 invested across mature cohorts, indicating sustainable path to profitability at scale. IM8's operational velocity—one order every 27 seconds—demonstrates consistent demand generation and fulfillment capability.
Prenetics simultaneously raised full-year 2026 revenue guidance for IM8 to $210–$220 million, up from the prior $190–$210 million guidance, marking the second upward revision in 2026. The company projects annualized run-rate revenue of $300 million by year-end 2026 and full-year 2027 revenue exceeding $400 million. The company entered the financing from a position of financial strength with approximately $139 million in available capital, and reported that July 2026 was the first month of positive consolidated adjusted free cash flow, expected to persist going forward. This capital-efficient growth strategy—pairing strong inherent unit economics with non-dilutive marketing financing—positions IM8 to accelerate customer acquisition while maintaining balance sheet strength and preserving shareholder equity.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.